Myriad Raises Outlook as Denials Squeeze Labs
Diagnostic testing operators should watch denial and zero-pay rates, which Myriad says are driving reimbursement pressure.
Updated on Nov. 7, 2026 in Healthcare

Myriad Genetics raised the midpoint of its 2026 revenue outlook to $785 million, within a $780 million to $790 million range, and agreed to sell its Prenatal Health testing business to Labcorp. Operators in diagnostic testing and healthcare reimbursement should watch how the company is restructuring around payer pressure.
Why it matters
Myriad is attributing reimbursement pressure to a rise in zero-pay outcomes and denials, not to lower contract rates or changes in medical policy. Higher revenue per test partly offsets softness in Prenatal Health, and the planned divestiture is intended to reshape the company's growth and margin profile.
Myriad Genetics set a 2026 revenue outlook range of $780 million to $790 million, with its midpoint raised to $785 million. The company projects revenue growth to improve by more than 1 percentage point and gross margin by more than 5 percentage points once the Prenatal Health sale closes, though the prior-year baseline and sale value were not disclosed in the source material.
The players
Myriad Genetics
A diagnostic testing company focused on genetic and hereditary cancer testing, whose revenue depends heavily on payer reimbursement decisions.
Labcorp
A large U.S. clinical laboratory operator that offers a broad range of diagnostic testing services to providers and payers.
The details
Myriad says it is seeing reimbursement pressure driven by a growing share of tests that pay zero and by more denials, rather than by lower contract rates or policy changes. To respond, the company cites process improvements, AI-enabled workflows, and payer-specific market access efforts. The divestiture of Prenatal Health to Labcorp is intended to streamline the portfolio so that margin and growth improvements show up in the remaining business.
Timeline
2026: Revenue outlook range of $780 million to $790 million set.
November 7, 2026: Outlook update published following the Labcorp sale agreement.
After the planned sale: Revenue and gross margin improvements expected.
2027: Meaningful progress in bottom-line profitability expected.
Market Landscape
Myriad's reimbursement pressure is coming from payer-side denials and zero-pay outcomes rather than from contract rate cuts, which places the issue in claims processing rather than pricing. The planned sale of Prenatal Health to Labcorp shows a large diagnostic operator consolidating a specialized testing line, a move that reshapes competition in prenatal testing.
Operators in healthcare and diagnostics should track claim denial and zero-pay rates as a core revenue line, since they can erode income even when contract rates hold. Businesses that bill or depend on lab reimbursement should review their payer-specific documentation and appeals processes with qualified billing advisors.
The takeaway
Revenue pressure from denials can build even with stable contract rates, so track denial and zero-pay rates alongside pricing. Myriad's projected margin gains after the Prenatal Health sale are management expectations, so compare them against reported results in future quarters.
Further reading
For more on how diagnostic testing companies are navigating payer rules, explore our Healthcare coverage.
Source note: This article includes information reported by TokenPost.




